Bora CDMO Bora CDMO

X
[{"orgOrder":0,"company":"Accord BioPharma","sponsor":"Eversana","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Accord Bio and EVERSANA Announce Partnership to Support the Launch of CAMCEVI","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Accord BioPharma","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts for Review BLA for DMB-3115 of Dong-A ST, a Proposed Biosimilar to Stelara\u00ae (Ustekinumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2024","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"}]

Find Clinical Drug Pipeline Developments & Deals by Accord BioPharma

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            DMB-3115 (ustekinumab-biosimilar) is an IL-12/23 inhibitor which is being evaluated in phase 3 clinical trials for the treatment of patients with moderate-to-severe chronic plaque psoriasis.

            Lead Product(s): Ustekinumab

            Therapeutic Area: Dermatology Product Name: DMB-3115

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Intas Pharmaceuticals

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 05, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            CAMCEVI is the first-ever ready-to-inject sterile formulation of leuprolide for subcutaneous injection that comes in a pre-filled syringe with no mixing required. In an open-label, single-arm study of 137 adults who received 42mg of CAMCEVI on Day 0 and Week 24.

            Lead Product(s): Leuprolide Acetate

            Therapeutic Area: Oncology Product Name: Camcevi

            Highest Development Status: Approved Product Type: Peptide

            Partner/Sponsor/Collaborator: Eversana

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership June 29, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY